Alnylam Pharmaceuticals | ALNY - 销售收入

股票价格

301.30

每天变化

-0.81 -0.27%

每月一次

-4.68%

每年

14.46%

Q2 预测

299.00

金融业

USD

USD 4.97B

现金及等价物

USD 1.66B

USD 267.72M

USD 4.05B

USD 1.47B

USD 1.31B

USD 29.4M

USD 145.22M

2.23K

EPS每股收益

USD 1.25

股本和储备

USD 789.18M

USD 829.31M

债务利息支出

USD 129.34M

USD 28.68M

USD 2.48B

USD 39.15B

USD 186.42M

USD 965.32M

USD 29.4M

普通股股本

USD 132.38M

170.7

USD 161.14M

USD 1.1B

销售和管理费用

USD 285.06M

USD 82.72M

贸易债权人

USD 115.72M

应收帐款人

USD 777.57M

	销售	更改		日
Acadia Pharmaceuticals	USD 284M		5.4M	2025-12
Agios Pharmaceuticals	USD 18.8M		1.17M	2026-03
Alnylam Pharmaceuticals	USD 1.1B		150M	2025-12
Amgen	USD 9.9B		340M	2025-12
Arrowhead Research	USD 264.03M		7.56M	2025-12
BioCryst Pharmaceuticals	USD 406.56M		247.16M	2025-12
BioMarin Pharmaceutical	USD 875M		99M	2025-12
Incyte	USD 1.27B		240M	2026-03
Ionis Pharmaceuticals	USD 246M		43M	2026-03
Moderna	USD 678M		342M	2025-12
Neurocrine Biosciences	USD 805.5M		10.6M	2025-12
Novartis	USD 13.11B		750M	2026-03
PTC Therapeutics	USD 164.7M		46.3M	2025-12
Regeneron Pharmaceuticals	USD 3.6B		280M	2026-03
Sangamo BioSciences	USD 356K		125K	2024-06
Sanofi	EUR 12.14B		65M	2026-03
Sarepta Therapeutics	USD 442.9M		43.5M	2025-12
Takeda	JPY 1.19T		80B	2025-12
Tectonic Therapeutic	USD 0		0	2024-12
Ultragenyx Pharmaceutical	USD 207M		47M	2025-12
Vertex Pharmaceuticals	USD 3.19B		110M	2025-12
Xencor	USD 28.24M		7.24M	2025-12